Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance.
about
Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stressSerum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.Proproliferative functions of Drosophila small mitochondrial heat shock protein 22 in human cells.Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.Proteomic analysis of liver in miniature pigs according to developmental stages using two-dimensional electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry.Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.Breast cancer proteomics: clinical perspectives.Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.Quantification of isotope encoded proteins in 2-D gels using surface enhanced resonance Raman.Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotypeRegulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications.Application of proteomics in the study of rodent models of cancer.Estrogen receptor-β in mitochondria: implications for mitochondrial bioenergetics and tumorigenesis.
P2860
Q28295105-6AAC9C8C-559E-4EEA-A698-C198EC610B36Q33514817-AAC1C52E-EEDC-4B9C-93C4-90FB57098451Q33662149-3F430020-5FBC-45A3-8279-4D5A2090F4C8Q34857146-8083B636-13D9-498B-9CE1-18ED1071821BQ35012375-4FC1D6ED-D4B7-4294-A9F1-6C142F520AE7Q36263003-41778292-13AA-404A-8037-EC8D50F253D7Q36388185-6229D448-9003-4D46-82DB-22DC15B8AC5FQ36717346-BBBF47E7-4F04-49DA-A1E8-DB3AD99E8784Q36787062-653CA3C9-E1FB-404E-A179-8F6CA9229DECQ37008882-5A9D7BB1-FD98-4FE2-BD7E-4B43104C5EC8Q37125893-C498BFF6-032A-4018-8E33-6A4EBCA0F456Q37131365-0A3B84D6-5428-42B9-B241-92B250009234Q37348421-57D18914-C5F2-4EDD-8E82-3240D67DF40EQ38194543-BC0B960A-ECD0-4D2B-BCEC-AF7043BE87F3Q38572516-589C5C21-3E10-4D0A-B455-80C0E9882DED
P2860
Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Proteomics of xenografted huma ...... lated to tamoxifen resistance.
@ast
Proteomics of xenografted huma ...... lated to tamoxifen resistance.
@en
type
label
Proteomics of xenografted huma ...... lated to tamoxifen resistance.
@ast
Proteomics of xenografted huma ...... lated to tamoxifen resistance.
@en
prefLabel
Proteomics of xenografted huma ...... lated to tamoxifen resistance.
@ast
Proteomics of xenografted huma ...... lated to tamoxifen resistance.
@en
P2093
P356
P1433
P1476
Proteomics of xenografted huma ...... lated to tamoxifen resistance.
@en
P2093
Iduna Fichtner
Lila Castellanos-Serra
Maylin Diaz
Michael Becker
Yassel Ramos
P2860
P304
P356
10.1002/PMIC.200500151
P577
2006-02-01T00:00:00Z